Skip to Content
Merck

HT110216

Eosin Y Solution, Aqueous

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.47
UNSPSC Code:
41116124
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


form

solution

Quality Level

shelf life

Expiry date on the label.

IVD

for in vitro diagnostic use

concentration

0.5 % (w/v) in water

application(s)

hematology
histology

storage temp.

room temp

Application

General purpose cytoplasmic counterstain. Used with hematoxylin and eosin staining.

Other Notes

Certified Eosin Y, 0.5% (w/v) in water. Not acidified.


Still not finding the right product?

Explore all of our products under Eosin Y Solution, Aqueous


Storage Class

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Frederik Denorme et al.
Blood, 127(19), 2337-2345 (2016-03-02)
Rapid vascular recanalization forms the basis for successful treatment of cerebral ischemia. Currently, tissue plasminogen activator (t-PA) is the only approved thrombolytic drug for ischemic stroke. However, t-PA does not always result in efficient thrombus dissolution and subsequent blood vessel
Kenneth C Valkenburg et al.
Oncotarget, 8(46), 80265-80277 (2017-11-09)
Prostate cancer is the most diagnosed non-skin cancer in the US and kills approximately 27,000 men per year in the US. Additional genetic mouse models are needed that recapitulate the heterogeneous nature of human prostate cancer. The Wnt/beta-catenin signaling pathway
Senna Staessens et al.
Haematologica, 105(2), 498-507 (2019-05-03)
Ischemic stroke is caused by a thromboembolic occlusion of cerebral arteries. Treatment is focused on fast and efficient removal of the occluding thrombus, either via intravenous thrombolysis or via endovascular thrombectomy. Recanalization, however, is not always successful and factors contributing